Extra-vascular modeling MCQs With Answer

Extra-vascular modeling MCQs With Answer

Introduction: This quiz collection focuses on extravascular modeling — a core topic in Advanced Biopharmaceutics & Pharmacokinetics for M.Pharm students. It covers theoretical and applied aspects of drug absorption from non-intravenous routes, including first- and zero-order absorption, flip-flop kinetics, transit-compartment and deconvolution approaches, Wagner–Nelson and Loo–Riegelman methods, lag time, mean absorption time, and factors affecting oral bioavailability. Questions emphasize model selection, parameter interpretation, mathematical relationships (ka, ke, V/F, CL/F), and real-world formulation implications like dissolution- or permeability-limited absorption, enterohepatic recirculation, and controlled-release behavior. Use this set to test and deepen your mechanistic understanding and problem-solving skills in extravascular kinetics.

Q1. In a one-compartment extravascular model with first-order absorption, which primary assumption underlies the model?

• The absorption process is saturable and dose-dependent
• The drug distributes instantly and homogeneously into a single compartment while absorption follows first-order kinetics
• The elimination follows zero-order kinetics irrespective of concentration
• Bioavailability is always unity and independent of formulation

Correct Answer: The drug distributes instantly and homogeneously into a single compartment while absorption follows first-order kinetics

Q2. Flip-flop kinetics is observed when which condition holds true for the absorption (ka) and elimination (ke) rate constants?

• ka >> ke, so absorption is much faster than elimination
• ka ≈ ke, resulting in indistinguishable phases
• ka < ke, so absorption is slower than elimination and governs the terminal slope
• ka = 0, indicating no absorption

Correct Answer: ka < ke, so absorption is slower than elimination and governs the terminal slope

Q3. The Wagner–Nelson method is used to:

• Estimate the fraction of drug absorbed over time for a one-compartment model using plasma concentration and AUC data
• Separate distribution from elimination in a two-compartment model without IV data
• Directly compute absolute bioavailability without any IV reference
• Predict intestinal permeability from in vitro dissolution data

Correct Answer: Estimate the fraction of drug absorbed over time for a one-compartment model using plasma concentration and AUC data

Q4. The Loo–Riegelman method is particularly appropriate when:

• Analyzing one-compartment first-order absorption data without needing IV information
• Determining fraction absorbed for two-compartment disposition and requiring IV pharmacokinetic parameters
• Estimating mean absorption time from single-dose oral data in nonlinear kinetics
• Modeling controlled-release zero-order absorption exclusively

Correct Answer: Determining fraction absorbed for two-compartment disposition and requiring IV pharmacokinetic parameters

Q5. Mean absorption time (MAT) can be calculated as:

• The difference between Tmax and Cmax
• The difference between mean residence time after extravascular dosing (MRTpo) and MRT after IV dosing (MRTiv)
• The reciprocal of the absorption rate constant (1/ka) only
• The time at which 50% of the dose is absorbed

Correct Answer: The difference between mean residence time after extravascular dosing (MRTpo) and MRT after IV dosing (MRTiv)

Q6. Transit compartment models are useful because they:

• Assume instantaneous absorption without delay
• Represent absorption delay and variability by a chain of sequential transit compartments producing a gamma-like absorption profile
• Only model zero-order release kinetics from dosage forms
• Eliminate the need to estimate ka or lag time

Correct Answer: Represent absorption delay and variability by a chain of sequential transit compartments producing a gamma-like absorption profile

Q7. Zero-order absorption is characterized by which of the following?

• An absorption rate proportional to the remaining drug at the absorption site
• A constant absorption rate independent of drug concentration at the site, often seen with certain controlled-release systems
• An absorption rate that follows Michaelis–Menten saturation kinetics
• Immediate and complete absorption at time zero

Correct Answer: A constant absorption rate independent of drug concentration at the site, often seen with certain controlled-release systems

Q8. Oral bioavailability (F) can be mechanistically expressed as:

• F = Fraction metabolized in liver × Fraction metabolized in gut
• F = Fa × Fg × Fh, representing fraction absorbed, fraction escaping gut wall metabolism, and fraction escaping hepatic first-pass
• F = CL/V, where CL is clearance and V is volume of distribution
• F = ka/ke for first-order models

Correct Answer: F = Fa × Fg × Fh, representing fraction absorbed, fraction escaping gut wall metabolism, and fraction escaping hepatic first-pass

Q9. Deconvolution in extravascular modeling is primarily used to:

• Estimate elimination half-life without any IV reference
• Determine the in vivo absorption rate-time profile by using the known disposition (unit impulse response) and observed plasma concentrations
• Compute Cmax directly from dose and Vd
• Replace the need for noncompartmental analysis

Correct Answer: Determine the in vivo absorption rate-time profile by using the known disposition (unit impulse response) and observed plasma concentrations

Q10. For a first-order absorption and elimination model, Tmax behavior indicates that:

• Tmax is independent of both ka and ke
• Tmax = ln(ka/ke)/(ka − ke), therefore Tmax increases as ka decreases relative to ke
• Tmax always equals 1/ka
• Tmax is directly proportional to bioavailability

Correct Answer: Tmax = ln(ka/ke)/(ka − ke), therefore Tmax increases as ka decreases relative to ke

Q11. A characteristic cause of a double-peak concentration–time profile after oral dosing is most commonly:

• Saturable renal clearance at therapeutic concentrations
• Enterohepatic recirculation or secondary absorption due to biliary excretion
• Immediate intravenous contamination during oral administration
• First-pass hepatic extraction alone without any secondary release

Correct Answer: Enterohepatic recirculation or secondary absorption due to biliary excretion

Q12. Saturable intestinal uptake leading to nonlinear absorption is best described by which statement?

• Absorption rate increases linearly with dose at all concentrations
• At higher doses carrier-mediated transport may approach Vmax, so fractional absorption decreases and AUC increases less than proportionally
• Permeability always increases with dose
• First-pass metabolism becomes irrelevant in saturable absorption

Correct Answer: At higher doses carrier-mediated transport may approach Vmax, so fractional absorption decreases and AUC increases less than proportionally

Q13. After oral dosing, estimated pharmacokinetic volumes are often reported as V/F. What does this imply?

• V/F equals the true physiological volume of distribution, independent of bioavailability
• V/F is an apparent volume that conflates true V with unknown bioavailability, so absolute V cannot be determined without F
• V/F is only used for IV dosing and not for extravascular routes
• V/F indicates that distribution is instantaneous and independent of dose

Correct Answer: V/F is an apparent volume that conflates true V with unknown bioavailability, so absolute V cannot be determined without F

Q14. When absorption is permeability-limited (e.g., BCS class III), which strategy is least likely to improve systemic exposure?

• Increasing drug solubility in the gastrointestinal fluid
• Using permeation enhancers or transport modulators
• Formulating as nanoparticles to improve intestinal uptake
• Altering pH microenvironment to increase membrane permeation

Correct Answer: Increasing drug solubility in the gastrointestinal fluid

Q15. For a one-compartment model with first-order absorption and elimination, the plasma concentration-time equation after an oral dose is:

• C(t) = (F · Dose / V) · (e^{−ke·t} − e^{−ka·t})
• C(t) = (F · Dose · ka)/(V(ka − ke)) · (e^{−ke·t} − e^{−ka·t})
• C(t) = (Dose/V) · e^{−ka·t}
• C(t) = (F · Dose)/(CL) · (1 − e^{−ke·t})

Correct Answer: C(t) = (F · Dose · ka)/(V(ka − ke)) · (e^{−ke·t} − e^{−ka·t})

Q16. In deconvolution terminology, the “unit impulse response” refers to:

• The absorption profile after oral dosing normalized to dose
• The plasma concentration-time curve resulting from an instantaneous unit input (e.g., unit bolus) that characterizes disposition
• The dissolution profile of the dosage form in vitro
• The cumulative fraction excreted unchanged in urine

Correct Answer: The plasma concentration-time curve resulting from an instantaneous unit input (e.g., unit bolus) that characterizes disposition

Q17. A key assumption of the Wagner–Nelson approach is that:

• Pharmacokinetics are nonlinear and multi-compartmental
• The drug follows linear kinetics and a one-compartment disposition model with instantaneous distribution within that compartment
• Bioavailability changes with time during absorption
• Elimination is zero-order

Correct Answer: The drug follows linear kinetics and a one-compartment disposition model with instantaneous distribution within that compartment

Q18. When flip-flop kinetics exists but is not recognized, which PK parameter derived from oral data is most likely to be misinterpreted?

• Cmax, because it will always be overpredicted
• Apparent terminal half-life, because it will reflect the absorption rate rather than true elimination half-life
• Volume of distribution estimated from IV data
• Bioavailability, which becomes exactly equal to unity

Correct Answer: Apparent terminal half-life, because it will reflect the absorption rate rather than true elimination half-life

Q19. Increasing absorption lag time (Tlag) while keeping extent of absorption constant will most likely:

• Decrease AUC substantially because less drug is absorbed
• Shift Tmax to a later time and may reduce Cmax, but AUC remains essentially unchanged
• Increase bioavailability by bypassing first-pass metabolism
• Convert first-order absorption into zero-order absorption

Correct Answer: Shift Tmax to a later time and may reduce Cmax, but AUC remains essentially unchanged

Q20. For modeling complex controlled-release oral formulations that show delayed and multiple absorption peaks, the most flexible mechanistic approach is typically:

• Using a simple single-compartment first-order absorption model with no lag time
• Applying transit-compartment or multi-input convolution models to represent delays, variable release and multiple absorption events
• Always using Loo–Riegelman method regardless of compartmental behavior
• Relying solely on noncompartmental analysis to capture peak structure

Correct Answer: Applying transit-compartment or multi-input convolution models to represent delays, variable release and multiple absorption events

Download